Although there are no specific biomarkers associated with increased risk of CVD and PCa treatment, biomarkers like BNP (Brain Natriuretic Peptide) and troponin may be helpful to monitor to assess the risk of cardiovascular events [66]. This evidence concerns the gene NPPB and posterior cortical atrophy.